StemCell Therapy

Highlights

Events and Activities

NIBGE Email

Welcome to NIBGE

PAEC has clear mandates on the safe use of modern sciences with an aim to improve the socio economic growth of the country. NIBGE is one of the main biotechnology institutes of the four bioscience centers of PAEC and was formally inaugurated by the President of Pakistan in 1994. It is also an affiliate center of ICGEB. The institute is a focal point of modern biotechnology and provides a technology receiving unit to help the development of country through applications of modern biotechnology and genetic engineering. The research programs at NIBGE are mainly aimed at improving agriculture, health, environment and industry and are supported by national and international financial grants. The institute research facilities include state of the art equipments supported by technical services, IT facility and a National Library for Biological Sciences. The institute now offers several services and marketable products. The educational programs leading to MPhil and PhD degrees have also been incorporated in the institutes mandate for the development of human resources in modern sciences.

Announcement

Interview Schedule of M.Phil (Biotechnology)

Featured News

Read more here:
Home :: National Institute for Biotechnology and Genetic ...

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that investigators presented results from the neratinib arm of the Phase II Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT Trial) at the 2021 Society for Neuro-Oncology Annual Meeting. The presentation, entitled Preliminary results of the neratinib arm in the Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): a phase II platform trial using Bayesian adaptive randomization, was presented as an oral presentation in the Abstract Session: Clinical Trials II Session. A copy of the presentation is available on the Puma Biotechnology website.

The INSIGhT trial is a multisite investigator-initiated Phase II screening adaptive platform trial where patients with newly diagnosed unmethylated glioblastoma who are IDH R132H mutation negative and with genomic data available for biomarker grouping are eligible. All patients receive radiation therapy and temozolomide and then patients are randomized to receive either adjuvant temozolomide or adjuvant treatment with an experimental agent (neratinib). At the initiation of INSIGhT, three experimental arms, each with a proposed genomic biomarker, are tested simultaneously. Initial randomization is equal across arms. As the trial progresses, randomization probabilities adapt on the basis of accumulating results using Bayesian estimation of the biomarker-specific probability of treatment impact on progression-free survival. Treatment arms were allowed to drop because of low probability of treatment impact on overall survival. The primary endpoint of INSIGhT is overall survival (OS). Progression-free survival (PFS) analysis is used to influence randomization. For the neratinib arm of the trial, patients received 240 mg of neratinib daily as a single agent with mandatory loperamide prophylaxis.

For the neratinib arm of the trial, there were 149 patients in the intent-to-treat population, including 81 patients treated with neratinib and 68 patients in the control arm. For the intent-to-treat population, PFS was not significantly longer (HR 0.75; p=0.12, log rank test) with neratinib (median 6.0 months) versus the control arm (median 4.7 months) and there was no significant improvement in OS (HR 1.01; p=0.75) between neratinib (median 13.8 months) vs. the control arm (median 14.7 months). For patients with activation of the EGFR pathway, defined as patients with either EGFR amplification or mutation, PFS was significantly longer (HR 0.58; p=0.04, log rank test) with neratinib (median 6.3 months) vs. the control arm (median 4.6 months); however, there was no significant improvement in overall survival (HR 0.97; p= 0.94) between neratinib (median 14.4 months) vs. the control arm (median 15.3 months).

Neratinib was generally well tolerated in the trial and toxicities for neratinib were similar to that previously described. For the 81 patients treated with neratinib, there were 6 cases (7.4%) of grade 3 diarrhea and no cases of grade 4 diarrhea. No new toxicity signals were identified in the trial.

Isabel Arrillaga-Romany, MD, PhD, Director of Neuro-Oncology Clinical Trials at Mass General Cancer Center, an investigator on the trial who presented the data at SNO, said, Although preliminary results did not achieve the primary endpoint, subgroup analyses demonstrated improved PFS in patients with EGFR activation and a non-significant trend toward improved overall survival in patients with EGFRVIII mutations, which could warrant further investigation. Additionally, we are very pleased that this trial reinforced feasibility of randomized Bayesian adaptive platform trials for newly diagnosed glioblastoma.

Alan H. Auerbach, Chief Executive Officer and President of Puma, added, We would like to thank the INSIGHT trial investigators and the patients for their participation in the trial. This is the first data demonstrating an effect of neratinib in EGFR amplified or mutated glioblastoma. While we are not looking to pursue further clinical investigations of neratinib in this indication, we are evaluating the potential to develop a backup compound HKI-357, which has preclinically demonstrated better EGFR activity, in this indication.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

Further information about Puma Biotechnology may be found at http://www.pumabiotechnology.com.

IMPORTANT SAFETY INFORMATION

NERLYNX (neratinib) tablets, for oral use

INDICATIONS AND USAGE: NERLYNX is a kinase inhibitor indicated:

CONTRAINDICATIONS: None

WARNINGS AND PRECAUTIONS:

ADVERSE REACTIONS:

The most common adverse reactions (reported in 5% of patients) were as follows:

To report SUSPECTED ADVERSE REACTIONS, contact Puma Biotechnology, Inc. at 1-844-NERLYNX (1-844-637-5969) or FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch.

DRUG INTERACTIONS:

USE IN SPECIFIC POPULATIONS:

Lactation: Advise women not to breastfeed.

Please see Full Prescribing Information for additional safety information.

To help ensure patients have access to NERLYNX, Puma has implemented the Puma Patient Lynx support program to assist patients and healthcare providers with reimbursement support and referrals to resources that can help with financial assistance. More information on the Puma Patient Lynx program can be found at http://www.NERLYNX.com or 1-855-816-5421.

Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties that could cause Pumas actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, any adverse impact on Pumas business or the global economy and financial markets, generally, from the global COVID-19 pandemic, and the risk factors disclosed in the periodic and current reports filed by Puma with the Securities and Exchange Commission from time to time, including Pumas Annual Report on Form 10-K for the year ended December 31, 2020. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Puma assumes no obligation to update these forward-looking statements, except as required by law.

Originally posted here:
Puma Biotechnology Presents Data from the Neratinib Arm of the INSIGhT Trial at the 2021 SNO Annual Meeting - Business Wire

BOSTON--(BUSINESS WIRE)-- GRO Biosciences Inc. (GRObio), an emerging biotechnology company leveraging groundbreaking science to expand the amino acid alphabet and deliver on the promise of protein therapeutics, today announced the hiring of veteran industry executive, Edward Tad Stewart, who joins the team as Chief Business Officer (CBO).

Mr. Stewart has worked extensively in business and corporate development in the biotechnology and pharmaceutical space for more than 20 years. He has played an integral strategic role in scaling platform biotechnology companies from early stages through FDA-approval and product launch. Mr. Stewart served most recently as Chief Business Officer of Ribon Therapeutics. Prior to his role at Ribon he served as President and CEO of Commense, Inc., Chief Business Officer of Crescendo Biologics, and spent many years with Merrimack Pharmaceuticals in various roles, including SVP of Business Development and Head of Commercial. Mr. Stewart received his MBA from Cornell University.

We are thrilled to have Tad join our executive team. His deep experience in business development and transactions will be instrumental to our partnering activities, and his expertise in product development will accelerate our commercialization efforts, said Daniel J. Mandell, PhD, Co-Founder and Chief Executive Officer of GRO Biosciences. Tad is an established leader in biotechnology, and his unique combination of transactional and strategic savvy will be a great asset to GRObio as we continue to advance our platform and pipeline.

About GRO Biosciences

GRO Biosciences (GRObio) is leveraging groundbreaking science to expand the amino acid alphabet and deliver on the promise of protein therapeutics. The Company is transforming treatments for increasingly prevalent chronic medical conditions including autoimmune and metabolic diseases to improve the lives of patients. GRObio is applying its platform to advance partnered and collaborative programs, as well as its own pipeline of protein therapeutics bearing unique NSAA (non-standard amino acid) chemistries. The Companys NSAA therapeutics feature previously unattainable capabilities including unprecedented duration of action and precise regulation of the immune system. GRObio, co-founded by George Church, PhD of Harvard Medical School in 2016, is headquartered in Cambridge, MA. Find GRObio on LinkedIn, Twitter, Instagram, Facebook and the web at grobio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211116005427/en/

Read more from the original source:
GRO Biosciences Strengthens Management Team With Appointment of Veteran Biotechnology Executive, Edward Stewart as Chief Business Officer - BioSpace

Polymerase Chain Reaction (PCR) Sales to Surpass US$ 12 Bn through 2031 as Adoption of Real-Time PCR Surges amid COVID-19

Fact.MRs latest study discusses factors affecting the polymerase chain reaction (PCR) market growth. It provides in-depth analysis of various market segments, including product and end user across seven major regions. The report further profiles leading PCR manufacturers and examines the effect of their growth strategies on the global market.

Fact.MR A Market Research and Competitive Intelligence Provider: According to the latest Fact.MR analysis, the global polymerase chain reaction (PCR) market will reach US$ 3.6 Bn by the end of 2021. Owing to the surging demand for PCR products, the overall market is projected to register growth at 10% CAGR between 2021 and 2031.

Sales in the PCR market are expected to increase with rising prevalence of target diseases and genetic disorders. Also, factors such as growing popularity of portable PCR testing kits, advancements in PCR technology, and increasing government funding for research activities will facilitate the growth in the market.

PCR has emerged as an ideal technique for the amplification of DNA sequences. It is a simple and cost-effective technique which produces results rapidly. It is an extensively used technique in medical laboratory research for a wide range of applications including biomedical research and criminal forensics.

The unprecedented outbreak of COVID-19 had a positive impact on the PCR market. It created huge demand for reliable and rapid detection techniques such as RT-PCR. Various companies also launched novel PCR test kits for the detection of virus.

Also, RT-PCR emerged as an ideal technique for detection of COVID-19 virus. It is significantly faster and has lower risk of contamination or errors.

Request a report sample to gain compressive insights at

https://www.factmr.com/connectus/sample?flag=S&rep_id=4861

As per Fact.MR analysis, PCR reagents will account for around 60% of total PCR market revenue by 2031. Rising demand for diagnostic tests and launch of new reagents specific to the test type are some key factors accelerating the demand for reagents used in polymerase chain reaction. Furthermore, RT PCR systems market to witness significant growth.

Regionally, North America will continue to dominate the PCR market, owing to the presence of a well-established healthcare infrastructure, continuous advances in clinical research, and high prevalence of genetic disorders such as Klinefelter's syndrome and Down syndrome. The region is poised to expand at a healthy growth rate of 7.5% annually.

However, Asia is projected to register the fastest growth on the back of increasing penetration of PCR products, rising government support, high prevalence of chronic diseases, and expanding healthcare infrastructure.

As the demand for PCR continues to rise, leading manufacturers are moving towards developing portable micro-scale devices. They also are introducing advanced PCR instruments, reagents and consumable that will allow quick nucleic acid amplification. This is expected to create growth opportunities for the market, says a Fact.MR analyst

Key Takeaways from Polymerase Chain Reaction Market Survey

Key Drivers

Key Restraints

To gain in-depth insights on Polymerase Chain Reaction Market, request methodology at

https://www.factmr.com/connectus/sample?flag=RM&rep_id=4861

Competitive Landscape

Key players operating in the polymerase chain reaction market are embracing advanced technologies for the development of new products. They have adopted various strategies such as mergers, partnerships, collaborations and manufacturing of advanced portable PCR products to increase their sales.

Some of the prominent players operating in the polymerase chain reaction market profiled by Fact.MR are:

More Insights on the Global Polymerase Chain Reaction Sales Outlook

Fact.MR provides an incisive coverage on global polymerase chain reaction market, presenting historical demand data (2016-2020) and forecast statistics for the period from 2021-2031. The study divulges compelling insights on the global demand for polymerase chain reaction with a detailed segmentation on the basis of:

Key Questions Covered in the Polymerase Chain Reaction Market Outlook Report

Explore Fact.MRs Coverage on the Healthcare Domain

Rapid Medical Diagnostic Kits Market- Infectious disease incidence has been steadily increasing over the last few decades, driving up demand for rapid medical diagnostic kits around the world. The need to detect novel pathogens that cause diseases is propelling the market forward. The low cost of rapid medical diagnostic kits is propelling market growth. Blood glucose testing is in high demand, and it has been growing at the quickest rate of all types of tests across all geographies. Technology advancements and strategic alliances by key market players have paved the way for rapid medical diagnostic kit innovations.

COVID-19 Saliva-based Detection Kits- COVID-19 detection treatments are likely to be in high demand due to the availability of COVID-19 virus variants and the continued danger of infection. Manufacturers are focusing on delivering cost-effective and convenient testing solutions as COVID-19 diagnostics become more widely employed. While vaccination initiatives have reduced the incidence rate in some nations, the virus continues to represent a serious concern and has a high occurrence rate due to mutant forms. Future viral mutant strains, as well as increased knowledge of COVID-19 testing, are predicted to maintain market growth.

PCR and Real-time PCR Molecular Diagnostics Market - The COVID-19 pandemic has boosted prospects for the growth of the PCR and real-time PCR molecular diagnostics market. Real-time (qPCR) and digital (dPCR) PCR tests have been used in a variety of healthcare settings to detect and diagnose potential cases. Because of its high sensitivity, healthcare providers have embraced PCR tests on a large scale. As a result of such trends, the global PCR and real-time PCR molecular diagnostics market is poised to soar to new heights, surpassing a significant revenue threshold in the coming decade.

About Fact.MR

Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. Spanning a wide range from automotive & industry 4.0 to healthcare, technology to even the most niche categories. 80% of Fortune 1000's trust us in critical decision making.

MarketNgage is powered by Fact.MR our Unified Intelligence Engine, a revolutionary Market Research Subscription platform with a flexible pricing to suit your needs.

You can access all our healthcare research reports by signing up with MarketNgagesMarket Research Subscriptionwith FREE credits. MarketNgage is powered by Fact.MR A Fully integrated research solution for seamless single-window access Widest coverage on emerging markets, nascent products, and disruptive technologies.

Contact:

Mahendra SinghUS Sales Office11140 Rockville PikeSuite 400Rockville, MD 20852United StatesTel: +1 (628) 251-1583E: sales@factmr.com

Source: Fact.MR

Continue reading here:
Polymerase Chain Reaction (PCR) Market to Expand by 3.3x as Application in Pharmaceutical & Biotechnology Industry Grows - BioSpace

Northampton, MA --News Direct-- Illumina

Were honored to be named to the prestigious 2021 Dow Jones Sustainability Indices for a third year in a row. Illumina received the highest score in the Pharmaceuticals, Biotechnology and Life Sciences industry.

Inclusion in the DJSI highlights our commitment to continuously improving and growing our Corporate Social Responsibility (CSR) program to build a more sustainable and equitable future for all. Our program focuses on accelerating access to genomics, supporting our communities, and integrating environmental stewardship into our operations.

If you would like to hear more about our CSR program, join us at our inaugural ESG Investor event on Tuesday Nov 16 at 11 am PT.

Thank you to all our employees for championing the needs of patients, customers, our communities, and our planet.

View additional multimedia and more ESG storytelling from Illumina on 3blmedia.com

View source version on newsdirect.com: https://newsdirect.com/news/illumina-named-to-2021-dow-jones-sustainability-indices-with-highest-score-in-pharmaceuticals-biotechnology-and-life-sciences-industry-107725996

Excerpt from:
Illumina Named to 2021 Dow Jones Sustainability Indices With Highest Score in Pharmaceuticals, Biotechnology and Life Sciences Industry - Yahoo...

The report on Global Food Biotechnology Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a basic definition of the product or service studied in the report. Along with this, it also contains a summary of the main applications of this product or service in various industrial sectors. In addition, market research experts have also provided information on the manufacture or production of the product or service and its distribution strategy.

Other important factors studied in the global Food Biotechnology market report include demand and supply dynamics, industrial processes, import and export scenarios, R&D development activities and cost structures. In addition, this report also calculates figures for demand and supply for consumption, production cost, gross profit margins and sales price for products.

Get FREE Sample copy of this Report with Graphs and Charts at:https://reportsglobe.com/download-sample/?rid=289972

The segmentation chapters enable readers to understand aspects of the market such as its products, available technology and applications. These chapters are written to describe their development over the years and the course they are likely to take in the coming years. The research report also provides detailed information on new trends that may define the development of these segments in the coming years.

Food Biotechnology Market Segmentation:

Food Biotechnology Market, By Application (2016-2027)

Food Biotechnology Market, By Product (2016-2027)

Major Players Operating in the Food Biotechnology Market:

Company Profiles This is a very important section of the report that contains accurate and detailed profiles for the major players in the global Food Biotechnology market. It provides information on the main business, markets, gross margin, revenue, price, production and other factors that define the market development of the players studied in the Food Biotechnology market report.

Global Food Biotechnology Market: Regional Segments

The different section on regional segmentation gives the regional aspects of the worldwide Food Biotechnology market. This chapter describes the regulatory structure that is likely to impact the complete market. It highlights the political landscape in the market and predicts its influence on the Food Biotechnology market globally.

Get up to 50% discount on this report at:https://reportsglobe.com/ask-for-discount/?rid=289972

The Study Objectives are:

This report includes the estimation of market size for value (million USD) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Food Biotechnology market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

Some Major Points from Table of Contents:

Chapter 1. Research Methodology & Data Sources

Chapter 2. Executive Summary

Chapter 3. Food Biotechnology Market: Industry Analysis

Chapter 4. Food Biotechnology Market: Product Insights

Chapter 5. Food Biotechnology Market: Application Insights

Chapter 6. Food Biotechnology Market: Regional Insights

Chapter 7. Food Biotechnology Market: Competitive Landscape

Ask your queries regarding customization at: https://reportsglobe.com/need-customization/?rid=289972

How Reports Globe is different than other Market Research Providers:

The inception of Reports Globe has been backed by providing clients with a holistic view of market conditions and future possibilities/opportunities to reap maximum profits out of their businesses and assist in decision making. Our team of in-house analysts and consultants works tirelessly to understand your needs and suggest the best possible solutions to fulfill your research requirements.

Our team at Reports Globe follows a rigorous process of data validation, which allows us to publish reports from publishers with minimum or no deviations. Reports Globe collects, segregates, and publishes more than 500 reports annually that cater to products and services across numerous domains.

Contact us:

Mr. Mark Willams

Account Manager

US: +1-970-672-0390

Email: [emailprotected]

Website: Reportsglobe.com

Original post:
Food Biotechnology Market 2021 Detailed Analysis of top Ventures with Regional Outlook | Key Companies: ABS Global, Arcadia Biosciences, AquaBounty...

NEW YORK, Nov. 6, 2021 /PRNewswire/ -- Crowdsourcing has become an increasingly popular way to develop machine learning algorithms to address many clinical problems in a variety of illnesses. Today at the American College of Rheumatology (ACR) annual meeting, a multicenter team led by an investigator from Hospital for Special Surgery (HSS) presented the results from the RA2-DREAM Challenge, a crowdsourced effort focused on developing better methods to quantify joint damage in people with rheumatoid arthritis (RA).

HSS Logo (PRNewsfoto/Hospital for Special Surgery)

Damage in the joints of people with RA is currently measured by visual inspection and detailed scoring on radiographic images of small joints in the hands, wrists and feet. This includes both joint space narrowing (which indicates cartilage loss) and bone erosions (which indicates damage from invasion of the inflamed joint lining). The scoring system requires specially trained experts and is time-consuming and expensive. Finding an automated way to measure joint damage is important for both clinical research and for care of patients, according to the study's senior author, S. Louis Bridges, Jr., MD, PhD, physician-in-chief and chair of the Department of Medicine at HSS.

"If a machine-learning approach could provide a quick, accurate quantitative score estimating the degree of joint damage in hands and feet, it would greatly help clinical research," he said. "For example, researchers could analyze data from electronic health records and from genetic and other research assays to find biomarkers associated with progressive damage. Having to score all the images by visual inspection ourselves would be tedious, and outsourcing it is cost prohibitive."

"This approach could also aid rheumatologists by quickly assessing whether there is progression of damage over time, which would prompt a change in treatment to prevent further damage," he added. "This is really important in geographic areas where expert musculoskeletal radiologists are not available."

Story continues

For the challenge, Dr. Bridges and his collaborators partnered with Sage Bionetworks, a nonprofit organization that helps investigators create DREAM (Dialogue on Reverse Engineering Assessment and Methods) Challenges. These competitions are focused on the development of innovative artificial intelligence-based tools in the life sciences. The investigators sent out a call for submissions, with grant money providing prizes for the winning teams. Competitors were from a variety of fields, including computer scientists, computational biologists and physician-scientists; none were radiologists with expertise or training in reading radiographic images.

For the first part of the challenge, one set of images was provided to the teams, along with known scores that had been visually generated. These were used to train the algorithms. Additional sets of images were then provided so the competitors could test and refine the tools they had developed. In the final round, a third set of images was given without scores, and competitors estimated the amount of joint space narrowing and erosions. Submissions were judged according to which most closely replicated the gold-standard visually generated scores. There were 26 teams that submitted algorithms and 16 final submissions. In total, competitors were given 674 sets of images from 562 different RA patients, all of whom had participated in prior National Institutes of Health-funded research studies led by Dr. Bridges. In the end, four teams were named top performers.

For the DREAM Challenge organizers, it was important that any scoring system developed through the project be freely available rather than proprietary, so that it could be used by investigators and clinicians at no cost. "Part of the appeal of this collaboration was that everything is in the public domain," Dr. Bridges said.

Dr. Bridges explained that additional research and development of computational methods are needed before the tools can be broadly used, but the current research demonstrates that this type of approach is feasible. "We still need to refine the algorithms, but we're much closer to our goal than we were before the Challenge," he concluded.

About HSS

HSS is the world's leading academic medical center focused on musculoskeletal health. At its core is Hospital for Special Surgery, nationally ranked No. 1 in orthopedics (for the 12th consecutive year), No. 4 in rheumatology by U.S. News & World Report (2021-2022), and the best pediatric orthopedic hospital in NY, NJ and CT by U.S. News & World Report "Best Children's Hospitals" list (2021-2022). HSS is ranked world #1 in orthopedics by Newsweek (2021-2022). Founded in 1863, the Hospital has the lowest complication and readmission rates in the nation for orthopedics, and among the lowest infection rates. HSS was the first in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center five consecutive times. The global standard total knee replacement was developed at HSS in 1969. An affiliate of Weill Cornell Medical College, HSS has a main campus in New York City and facilities in New Jersey, Connecticut and in the Long Island and Westchester County regions of New York State, as well as in Florida. In addition to patient care, HSS leads the field in research, innovation and education. The HSS Research Institute comprises 20 laboratories and 300 staff members focused on leading the advancement of musculoskeletal health through prevention of degeneration, tissue repair and tissue regeneration. The HSS Global Innovation Institute was formed in 2016 to realize the potential of new drugs, therapeutics and devices. The HSS Education Institute is a trusted leader in advancing musculoskeletal knowledge and research for physicians, nurses, allied health professionals, academic trainees, and consumers in more than 130 countries. The institution is collaborating with medical centers and other organizations to advance the quality and value of musculoskeletal care and to make world-class HSS care more widely accessible nationally and internationally. http://www.hss.edu.

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/researchers-present-global-effort-to-develop-machine-learning-tools-for-automated-assessment-of-radiographic-damage-in-rheumatoid-arthritis-301417942.html

SOURCE Hospital for Special Surgery

Read more:
Researchers Present Global Effort to Develop Machine Learning Tools for Automated Assessment of Radiographic Damage in Rheumatoid Arthritis - Yahoo...

Remote classes such as yoga, Pilates, and tai chi are beneficial for people with musculoskeletal problems such as osteoarthritis (OA), rheumatoid arthritis (RA), and osteoporosis, according to research presented at the American College of Rheumatology 2021 annual meeting.

After attending biweekly 60-minute low-intensity Zoom fitness classes at six-week increments, participants improved physically and became more socially active, say researchers at the Hospital for Special Surgery (HSS) in New York City.

RELATED: Whats Your Arthritis Lifestyle Type?

Out of the 355 people assessed (among a total of 6,779 participants), 161 self-reported a musculoskeletal condition. Affecting the joints, bones, or muscles, musculoskeletal conditions include inflammatory arthritis and other chronic conditions associated with pain, functional limitations, and disability.

Participants were mostly female, older than 60, and white. That group reported that with any level of participation at every six-week virtual exercise session, they achieved:

Those who said they attended twice a week or more for six weeks reported even more improvement:

Live remote exercise programs offer a two-way interactive experience: participants connect to a video conference or meeting remotely with a computer, smartphone, or tablet device, usually from their own home. During the class, people may have the opportunity to talk with others and get personal feedback from the instructor, who can see and hear them via the devices camera and microphone.

HSS offered a remote, live class that had to be taken at a scheduled time but provided direct interaction with the instructor and other students. Unlike prerecorded classes online (often free) that allow you to participate whenever you choose, the live classes allow for interaction and professional oversight. Online or on-demand fitness classes are similar to the one-way classes offered via recording on a videotape or DVD.

RELATED: 6 Simple Yoga Poses for Psoriatic Arthritis

According to the Centers for Disease Control (CDC), loneliness affects more than one-third of adults age 45 and and up and nearly one-fourth of adults age 65 and older. (Obviously, the COVID-19 pandemic made human connection vastly more difficult.) There are many health risks associated with social isolation, including dementia, mental health issues, and premature death.

A study published in June 2017 inQuality in Ageing and Older Adults found a strong connection between social isolation and loneliness and chronic musculoskeletal diseases. To work on that, the HSS research team built a social component into their exercise programs. We made sure our classes were structured to increase interactions with others. We promoted a dialogue before the class began so people could talk and catch up with each other. They said it helped promote social connections, says Titilayo Ologhobo, MPH, the director of outcomes and data analytics at HSS and the new studys author.

RELATED: Tai Chi Might Help Reduce Belly Fat in Middle-Aged and Older Adults

The team did not collect data comparing virtual and in-person classes, but the feedback they received was that people enjoyed the virtual program because of the time flexibility and the convenience of working out at home. Other barriers to exercise known to challenge people with arthritis and other conditions are physical accessibility, travel conditions, and pain with movement. Research published in Physical Therapy and Rehabilitation Journal found that people with osteoarthritis experienced the following obstacles to exercising regularly at in-person classes.

Ologhobo stresses that you shouldnt start any new exercise regimen before consulting with your healthcare provider. Your doctor can help you assess whether a given program is appropriate for your level of fitness and health. If you have moderate or severe disease, you may want to check in with a physical therapist who can evaluate the safety and efficacy of a given program for you and suggest specific resources. Here are some virtual sites that offer gentle exercise. Consider a trial class or trial membership before you make a financial commitment. If none of these work for you, ask your healthcare provider or physical therapist for suggestions.

The takeaway for rheumatologists and others who care for people with painful musculoskeletal conditions appears to be to encourage participation in these types of classes. Amid the uncertainties caused by the pandemic, shifting to virtual programming provided older adults with musculoskeletal conditions continued access to effective community programs and reduced the negative impact of isolation. Implementation of virtual online exercise programs can be successful when assessing the needs of your target audience, considering potential barriers to program participation, and tailoring virtual programs to meet patients specific needs, Ologhobo said in a press release.

RELATED:How Fitness Helps You Manage Chronic Disease

Continued here:
Livestreaming Fitness Classes Can Improve Pain, Joint Stiffness, and Fatigue - Everyday Health

There are also a number of factors which might make inflammation and pain worse. The main goals of arthritis treatments are to reduce symptoms and improve quality of life. Arthritis or other similar conditions that affect the joints, impacts more than 10 million people in the UK. People of all ages can suffer from the health issue, including children, though there are some modifiable risk factors that may help stave off the condition.

Arthritis is not a single disease, but instead a way of referring to joint pain or joint disease. There are more than 100 types of arthritis and related conditions.

Osteoarthritis and rheumatoid arthritis are the two most common types of arthritis.

Currently, the NHS notes that there is no cure for arthritis, but there are many treatments that can help slow it down.

There are also a number of factors that can increase your risk of developing the condition. If you have arthritis, your joints will most likely feel stiff and be hard to move, you may also find that the area around your joints may feel warm, look red or puffy.

READ MORE:The common mistake people make when showering that can be 'harmful' - pharmacist's warning

University Health says that incorporating foods high in omega-3 fatty acids, protein and fibre into your diet, may help reduce joint pain and inflammation.

Some foods can actually trigger inflammation, so if you have an arthritis diagnosis it may be worth cutting these down in yourdiet.

Itadds: On the other hand, there are certain foods you may want to avoid. Processed foods, food with added sugars and red meats may cause inflammation.

It suggests avoiding ice cream, fast food, cakes, bread and biscuits, as well as beef and pork.

DON'T MISS:

If you notice symptoms or are concerned about arthritis it is important to speak to your GP.

The NHS encourages those living with arthritis to eat a healthy and balanced diet and maintain a healthy weight.

They explain diets should consist of a variety of foods from all five food groups. These are fruit and vegetables, starchy foods, and meat, fish, eggs and beans.

The health body adds that you should include milk and dairy foods, and foods containing fat and sugar.

"Finding out whats causing your pain is key to finding the right treatment and self-help options, says Versus Arthritis (VA).

As well as causing pain and stiffness, inflammation can cause permanent damage to a joint, so starting effective treatment early on can help to minimise damage.

Its important to see a doctor if you get any new symptoms or if you have any trouble with drugs youre taking, VA adds.

Treatment for most arthritis aims to slow the condition's progress and minimise joint inflammation.

Read more from the original source:
Arthritis: Three of the 'worst foods' for causing inflammation - 'you may want to avoid' - Daily Express

Ayurvedic diet  |  Photo Credit: iStock Images

When you have arthritis, your body is already in an inflammatory state. One is battling pain and other symptoms that if left unattended can cause other chronic conditions such as obesity, heart disease and diabetes. Here's what Ayurveda says about pro-inflammatory foods and things to avoid.

The name for Rheumatoid Arthritis in Ayurvedic texts is "Amavata". Ayurvedic texts prescribe specific diet and treatment procedures such as Virechanakarma.

As per a study that is published in the Journal of Research in Ayurveda, Amavata is a disease in which vitiation of Vata Dosha and accumulation of Ama take place in joint(s), and it simulates rheumatoid arthritis (RA) in modern parlance. Shamana (conservative) and Shodhana (biological purification of the body) treatments are advised in Ayurveda whereas anti-inflammatory, analgesics, steroids, and disease-modifying antirheumatic drugs are required for its management as per modern medicine, which is not free from side effects.

The study cites the case of a lady patient with Rheumatoid Arthritis. "As the patient did not get any relief with Shamana Chikitsa (ayurvedic or modern medicinal treatment), it was decided to go for Shodhana Chikitsa (Panchakarma). The patient underwent Virechanakarma (therapeutic purgation) as per indication mentioned in the classics of Ayurveda."

After a follow-up of 1 year, the patient was found free from almost all signs and symptoms of Amavata. The quality of life was improved significantly and the patient was enjoying a normal healthy life with no exacerbation.

Asper a report in PlanetAyurveda.com, along with the medicines, the patient must also observe pathya (dos and don't) to help the healing process.

What to eat and what to banish from your platter?

Planet Ayurveda prescribes the following dos and don'ts where diet is concerned.

Cereals to consume: Quinoa, buckwheat, brown rice, oats, little millet, corn, Kamut, wheatCereals to avoid: Barley, Rye, White rice

Fruits to consume: Apple, Banana, Cherry, Avocado, Peaches, pear, pomegranate, Sapodilla, apricot, blueberry, amlaFruits to be avoided: All citrus fruits like lemon, oranges, sweet lemon, etc, strawberry, mango, kiwi

Vegetables to be consumed: Ridge gourd, pumpkin, spinach, potato, drumstick, carrot, broccoli, onion, ginger, beetroot, bitter gourd, round gourd, mushroom, bottle gourd, kale zucchini, turnips, beans.Vegetables to avoid: Tomatoes, eggplant or brinjal, radish

Pulses to consume: All pulses and legumesPulses to avoid: None but limit the use of Black gram/kidney beans

Dairy products to consume: Occasionally or limited intake of ghee, skimmed milk (by adding turmeric) and low-fat yoghurtDairy products to avoid: All the other milk products

Oils to be consumed: Sunflower oil, ghee, olive oil, mustard oil, rice bran oilOil to avoid: Canola oil, Palm oil, coconut oil

Ayurveda bans all stale food, bakery products, fried foods, pickles, refined sugar, vinegar, packaged food, processed and junk foods, says PlanetAyurveda.com. It also cites Ayurvedic texts that layimportance upon weightloss to beat arthritis. Yoga and massage as well as pranayam are stressed upon. Avoid spices, stress, and drinking at least 8-10 glasses of water, says Planet Ayurveda.

View post:
Foods that can worsen arthritis symptoms: Listen to Ayurveda-prescribed dos and don'ts - Times Now

Lisa Hilinski| Special to the Erie Times-News

With just 10 minutes of exercise a day, you can slow pains of aging

Apparently less than 10 minutes of walking a day may keep arthritis away. Buzz60's Maria Mercedes Galuppo has more.

Buzz60

As colder weather arrives, many arthritic patients are convinced the lower temperatures and varying barometric pressures can increase their pain.

Having more than a decade of experience training clients with arthritis, I find this to be true.

With that said, scientists have yet to provide actual evidence that lower temperatures or varying humidity make arthritis worse. Yet, they seem to believe their patients on some levelbecause the connectionbetween weather and arthritis has been studied a lot.

If youre someone whosearthritis tends to ignite at this time of year, here are some things we can tell you about your condition:

While everyone isunique, the consensus is that arthritis symptoms lessen with various types of movement. Positive outcomes have been shown with flexibility training andstrength training, as well as cardiovascular training.

Lisa Hilinski: Exercise can increase productivity at the workplace with happier, healthier employees

The worst thing you can do as someone with arthritis is sit around. While this holds true for any population, its particularly true for those with arthritis.

Sitting creates stiff joints, which results in more pain when its time to move around. You want to create more blood flow to your joints and keep those joints happy.

Regular exercise will be valuable for those with arthritis, but you dont need to be super structured.

Some days youre going to wake up feeling like a million bucks, and other days youll wake up feeling like a truck hit you. Its important to read your body and do what its telling you.

More Lisa Hilinski: Train your body to go in all directions to avoid injury, losing range of motion

On the days when youre feeling your worst, do something low impact, like general cardiovascular training. On the days when your body is feeling good, do some lower-impact strength training.

Use some lighter dumbbells and resistance bands, and give yourself a full body workout.

Flexibility training can be done every day and should be performed both statically and dynamically.

Overall, move your body to keep it happy this winter,and let your body tell you what it needs.

Lisa Hilinski is owner of Premier Personal Training.

View original post here:
Lisa Hilinski: What to know about effects on arthritis as colder temperatures arrive - GoErie.com

There are many simple lifestyle changes you can make to help manage arthritis. Could this herbal tea reduce inflammation and help with painful joints?

Arthritis is a very common condition caused by swelling around your joints and damage to the cartilage that keeps your joints moving.

The most common type of arthritis in the UK is osteoarthritis, which is most common in people over the age of 40, and most prevalent in women.

If you suspect you might have arthritis, its best to speak to your GP about possible treatments available for you.

Changes to your diet, such as cutting out foods known to cause inflammation, and eating more foods with anti-inflammatory properties, are often recommended to people with arthritis.

Some people with arthritis will also be advised to lose weight or maintain a healthy body weight, as being heavier can put more strain on your joints.

Could this 13p tea help to reduce arthritis pain?

READ MORE:Pfizer booster shot: Expect 'arthralgias' to be likely

The evidence available at the moment has focused on studies where participants take a more concentrated rosehip extract.

However, if you prefer to drink rosehip tea you can pick up a bag of 20 teabags for just 2.59 from Holland & Barrett.

Alternatively, you can try brewing your own dried rosehips in boiling water.

View post:
Arthritis diet: The 13p tea to reduce painful symptoms of arthritis - Express

Arthritis is a painful and debilitating condition that affects many millions of people in the UK.

While there is medication to help control the pain there are also many simple lifestyle and dietary changes that can help to manage it.

One natural remedy is contained in a very cheap and tasty herbal tea that could help ease joint pain, the Express reports.

Read more Coventry news

Arthritis is caused by swelling around the joints and damage to the cartilage that keeps joints moving.

Osteoarthritis is the most common type of arthritis in the UK.

It tends to affect people over the age of 40 and women in particular.

Anyone who feels they may have arthritis os advised to speak to their GP about possible treatments available.

But dietary changes and cutting out foods known to cause inflammation, as well as eating more foods with anti-inflammatory properties, are often recommended.

People who suffer from the condition may also be advised to lose weight as being heavier can put more strain on your joints.

So, could a 13p tea help to reduce arthritis pain?

Rosehip tea is a herbal tea made from the rose plant and has a floral but tart taste.

Rosehip was used by ancient civilisations as a natural remedy for many conditions, ranging from toothache to rabies.

Today rosehip extract is linked to many health benefits, including boosting the immune system, reducing inflammation and improving heart health.

Is it something that can help people manage arthritis?

Rosehip contains two substances believed to reduce joint inflammation and pain - polyphenols and anthocyanins.

Polyphenols are compounds found in plants and plant-based foods that are high in antioxidants.

Anthocyanins are a type of antioxidant known for their purple colour. It is the substance which gives blueberries, aubergines, red cabbages and blackberries their vibrant colours.

Rosehip is also high in vitamin C, which is noted for its antioxidant properties, as well as boosting the functioning of the immune system.

Research has been carried out on rosehips healthy properties.

One four-month study of 100 people with osteoarthritis, found taking five grams of rosehip extract every day, saw reduced pain for 65 per cent of those who took part.

Studies have also noted rosehip can have a positive effect on weight loss, which can help manage joint pain and arthritis.

A cup of rosehip tea is just three calories, so it makes for a great low-calorie alternative to sugary drinks. It is also caffeine free.

The evidence that is currently available as to its benefits has focused on studies where participants take a more concentrated rosehip extract.

But rosehip tea is a very cheap and easily available alternative.

You can pick up a bag of 20 teabags from Holland & Barrett for just 2.59.

If youre adventurous you could even try making some yourself by brewing your own dried rosehips in boiling water.

Keep up with the latest news with our email alerts directly to your inbox. Sign up here.

View original post here:
The 13p herbal tea that could help ease the pain caused by arthritis - Coventry Live

Excruciating arthritis symptoms can be decreased with this simple but powerful tea from South Asia.

Over 10 million people in the UK suffer from arthritis, a condition that can affect those of all ages.

Arthritis is a common health condition which causes chronic pain in your joints. It damages joints, bones and can impact other body parts depending on the type.

Osteoarthritis is the most common variant of the condition, accounting for 9 million cases and usually, but not exclusively, develops after the age of 40.

It initially affects the smooth cartilage lining of the joint, then once the cartilage lining starts to roughen and thin out, the tendons and ligaments have to work harder causing excruciating pain.

There are two types of arthritis, osteoarthritis and rheumatoid. While osteoarthritis is caused by day-to-day wear-and-tear, rheumatoid arthritis is when your body's immune system attacks the joint capsule, which houses all parts of the joint responsible for seamless movement.

The attacks can eventually result in the cartilage being totally destroyed, leaving the sufferer with painful bone-on-bone movement.

Inflammation in the body can make symptoms of both types significantly worse, but drinking this tea could significantly lessen your pain.

In a study published on the US National Library of Medicine National Institutes of Health, it found that an active compound in turmeric, called curcumin, was effective in reducing pain in patients with osteoarthritis.

Not only this, but they found patients experienced no side effects after drinking the tea.

Though it can't restore joints and cartilage to pre-arthritis condition, it reduces swelling responsible for much of the pain associated with the condition.

Turmeric tea has also been shown to relieve period pains of women, relaxing blood vessels around the uterus.

The active ingredient that reduces swelling in turmeric, curcumin, makes up only 3-5 percent of the spice. Therefore, those looking for a higher dose are recommend to take a daily curcumin supplement of 200 to 1000mg, that contains 95 percent curcuminoids.

Turmeric has long been used in South and South East Asian cooking and medicine. Numerous studies are underway exploring its medical potential in the West.

The NHS highlights these main signs as symptoms of arthritis:

If you are experiencing any of these symptoms, contact your healthcare provider.

Read more:
Arthritis: Experts hail powerful Asian tea that can dramatically decrease pain - Birmingham Live

TUESDAY, Nov. 2, 2021 (HealthDay News) -- Air pollution is associated with increased rheumatoid arthritis (RA) disease severity, according to a study published in the October issue of Rheumatology.

Giovanni Adami, M.D., Ph.D., from the University of Verona in Italy, and colleagues collected longitudinal data of patients affected by RA and the daily concentrations of air pollutants in the Verona area to examine the correlation between RA flares and air pollution in a case-crossover study. Exposure to pollutants was compared in the 30- and 60-day periods preceding an arthritic flare relative to the 30- and 60-day exposure preceding a low-disease activity visit.

Data were included for 888 RA patients with 3,396 follow-up visits. The researchers identified an exposure-response relationship between air pollutant concentration and the risk for having abnormal C-reactive protein (CRP) levels. The risk for having CRP levels 5 mg/L were increased for patients exposed to higher concentrations of air pollutants. In the 60-day period preceding a flare, concentrations of carbon monoxide, nitric oxide, nitrogen dioxide, oxides of nitrogen, particulate matter with a diameter of 2.5 m or less, and ozone were higher.

"The excessive risk was seen even at very low levels of exposure, even below the proposed threshold for the protection of human health," the authors write. "Our study has important and direct consequences. In order to reduce the burden of RA, public and environmental health policy makers should aim to diminish gaseous and particulate matter emissions to a larger extent than currently recommended."

Abstract/Full Text

Visit link:
Air Pollution Linked to Increased Rheumatoid Arthritis Severity - HealthDay News

Two kidney transplant patients who received a stem cell therapy developed by Talaris Therapeutics were able to come off all immunosuppressant drugs within a year, without any evidence of graft rejection.

The first findings from Talaris phase 3 trial of the cell therapy called FCR001 suggest it may be possible to eliminate the need entirely for patients to take what may be dozens of tablets daily after organ transplants, according to the US biotech.

While still preliminary, the experience with the two patients back up Talaris hope that giving a one-shot dose of FCR001 the day after an organ transplant could stimulate immune tolerance in the recipient, and avoid the side effects of current drug treatments such as infections, heart disease, and some forms of cancer.

The companys approach relies on administering haematopoietic stem cells from the individual who donated the organ, in order to generate what Talaris refers to as chimerism, with both donor and recipient cells present in the bone marrow. That allows the immune system to see the transplanted organ as self rather than foreign.

The first two recipients in Talaris FREEDOM-1 phase 3 trial had received FCR001 at least 12 months earlier, and showed stable kidney function, according to Talaris.

A larger group of five patients who were at least three months from the cell therapy maintained more than 50% chimerism in their T cells, which the biotech said was a sign of long-term, immunosuppression-free tolerance to the donated kidney in its phase 2 trials.

The FREEDOM-1 results reported at the American Society of Nephrology (ASN) meeting this week were accompanied by updated results from Talaris phase 2 study, in which all 26 patients originally weaned off immunosuppressants have continued to remain off them without rejecting their donated kidney.

Some transplant patients treated with Talaris therapy in earlier trials have now been off all immunosuppression for more than 12 years without signs of kidney rejection.

Talaris intends to enrol 120 subjects into the phase 3 trial, which is scheduled to generate results in 2023.

Earlier this year, Talaris raised $150 million via a Nasdaq listing that will be used to take FCR001 through the phase 3 programme in organ transplantation and as a treatment for rare autoimmune disease scleroderma.

It also recently started a phase 2 trial of the cell therapy to see if it is able to induce immune tolerance to a transplanted kidney in patients who received the transplant from a living donor up to a year prior to administration of FCR001.

Read the original post:
Talaris therapy ends need for immune drugs in transplant patients - - pharmaphorum

Most Americans understand the importance of maintaining a healthy regimen that includes a nutrient-dense diet, exercise at least several times a week, and self-care activities to de-stress. But in addition to that being good for a healthy weight and clear skin, and preventative for long-term health issues from cancer to diabetes, taking care of ourselves has the added benefit of boosting our immune systems to ward off everything from the common cold to the fluor at least help our bodies to fight illness when we get sick.

Our immune systems help to keep bacteria, toxins, and viruses at bay, and prevent us from getting sick from the diseases they cause. Immune systems further help remove unhealthy or infectious cells from our bodies and regulate the body's responses to otherwise harmless activity (whether food or our own bodies).

Theres no silver bullet for preventing or fighting disease, but its as good a time as any to discuss natural ways to keep our immune systems high-functioning.

To that end, Stackerscoured health studies, expert medical advice, nutrition facts, and recent headlines to deliver 25 natural ways to boost your immune system. The gallery includes interesting factsdid you know your body cant produce vitamin C on its own?and guidelines for optimizing your water intake and figuring out which foods function as the strongest antioxidants. Keep reading to learn more about 25 ways to naturally boost your immune system.

You may also like: States where the most people live in maternal health care deserts

Read the rest here:
25 natural ways to boost your immune system | Around The Web | laconiadailysun.com - The Laconia Daily Sun

Stanford biologists found that ovarian cancer cells evade the immune system by signaling that they are part of a developing fetus, according to an August research study published in Cell Reports.

Lead researcher and assistant professor of urology at Stanford Medicine Wendy Fantl and her team researched and sorted cells present within ovarian cancer tumors to understand the mechanism behind the quick growth of these tumors.

Close to 90% of ovarian cancer patients will survive for no more than five years, according to co-author and urology postdoctoral scholar Antonio Delgado-Gonzalez, who is part of the Fantl Lab. Delgado-Gonzalez also said that ovarian tumors typically present asymptomatically, making them difficult to detect early on.

This is a disease in great need of new effective treatments, Fantl said. While women may initially respond to treatments such as chemotherapy, most of them will relapse so we really wanted to understand what was going on.

Fantl and her research team analyzed over 800,000 cancer cells in 17 patients who had been newly diagnosed with ovarian cancer. They used a new technique called CyTOF developed by the lab of microbiology and immunology professor Garry Nolan. CyTOF makes it possible to analyze each intact cell as opposed to groups of similar cells, which allows the researchers to identify rarer subsets of cells. Each cell was sorted into a different category based on which proteins it expressed.

If you think about the tumor itself, it is a very complex tissue. You are going to find cells that give rise to the tumor, the resident immune cells and more, co-author and microbiology instructor Ermenlinda Porpiglia said. This single-cell analysis, or CyTOF, allows you to identify individual cell types. Resident immune cells refer to cells from the patients immune system.

Some of the cells in the immune systems line of defense, termed natural killer cells, typically recognize anything foreign within the body and proceed to kill it, according to co-author and Stanford pathology instructor Kevin Kolahi. A developing fetus would be viewed as a foreign object if this line of defense was not suppressed.

However, decidual natural killer cells contain a unique marker.

These [decidual] natural killer cells create an environment that is suppressive so the mother immune system does not attack the fetal immune system, Kolahi said.

Ovarian cancers exploit this mechanism. Researchers found a high number of cancer cells with a protein called CD9 present on their surface within the tumor, similar to the decidual natural killer cells that arise during a pregnancy. The cancer cells transfer CD9 to the natural killer cells within the body through a process called trogocytosis. This suppresses the immune response of the natural killer cells similar to how immune response is mediated when mothers have a developing fetus.

The tumor cells can continue to grow and form more aggressive tumors by evading the immune system.

With natural cells becoming less effective, the immunotherapy itself can become less effective, Porpiglia said.

These findings have important implications for the potential development of new forms of immunotherapy and possible screening tools. Fantl has procured another grant to continue her work. She will work with a collaborator in Milan, Italy to determine if detection of natural killer cells with CD9 is possible in earlier stages of ovarian cancers.

The work has definitely spawned many avenues for further research, and Im excited about that and for more mechanisms of immunotherapy to be discovered, Fantl said.

Read the original here:
Stanford study discovers how ovarian tumors avoid detection by the immune system - The Stanford Daily

People who already have had COVID-19 may have more reason to get vaccinated, with new findings suggesting that vaccination after infection can boost protection.

Under viral threat, the body first uses B cells to make antibodies against the invader, a process that can take up to 2 weeks. The immune system simultaneously creates memory B cells that can recognize the virus if it reappears and rapidly mounts a powerful secondary response.

In a series of shots, the first dose triggers the primary response. The follow-up doses activate the memory B cells, strengthening defenses against the pathogen.

These new results, published in Cell Reports , show that a SARS-CoV-2 infection, like a first vaccine dose, will elicit the primary response, as expected.

The researchers also found that a vaccine after the infection can set off the secondary memory B cell response, enhancing immune protection for those who already have had COVID-19. In fact, this secondary reaction exceeded responses after two vaccine doses in those with no history of SARS-CoV-2 infection.

The findings suggest that vaccination is particularly valuable for people who have already had COVID-19, ensuring a robust immune reaction if the virus finds them again.

Sources:

Cell Reports: "High-affinity memory B cells induced by SARS-CoV-2 infection produce more plasmablasts and atypical memory B cells than those primed by mRNA vaccines.

Wiley Online Library: Immune Responses: Primary and Secondary."

More:
Vaccine After COVID-19 Infection Boosts Immune Response: Study - Medscape

For David Gate, one of the first real litmus tests of whether a research career was for him came while dissecting retinas as a premed student studying psychology at the University of California, Santa Barbara. Working in the eye biology lab didnt really capture his imagination, and parts of the work were tedious, but Gate says that despite that, he loved the processthe basic work of doing experiments. I quickly became a lab rat all day and night, and was soon dissecting retinas better than anyone in the lab, Gate tells The Scientist.

After graduating in 2007, Gate went on to work as a lab technician with immunologist and Alzheimers disease researcher Terrence Town at Cedars-Sinai Hospital in Los Angeles. The connection between the brain and the immune system intrigued Gate, and he decided to pursue a PhD in brain sciences in Towns lab at the University of Southern California, studying the role of the immune system in pediatric brain cancer. But it was as a postdoc working in the lab of neuroscientist Tony Wyss-Coray at Stanford University that Gate would make his biggest impact yet.

The main focus of his research was brain rejuvenation, but on weekends, Gate was working a side project using patients blood samples to identify links between the immune system and Alzheimers disease. After months of collecting data on the levels of different immune cell types in the blood to see if there were any changes associated with the disease, Gate approached Wyss-Coray and made a proposal: that Gate stop his brain rejuvenation work and focus on his Alzheimers research full time.

I think that took quite a bit of courage, says Andrew C. Yang, a friend and former Stanford labmate of Gates who is now starting a lab studying the blood-brain barrier at the University of California, San Francisco. While everyones accounts of the lab paint a convivial picture, starting a whole new project is not without risk. These experiments are not cheap, says Yang. He puts his reputation on the line with Tony when he says, Hey, lets go fund it. Lets do it. It takes a certain type of vision.

Wyss-Coray, it turned out, was on board. But he and Gate wanted a way to look for immune changes in the brain, as opposed to just the blood. Gate suggested they look at cerebrospinal fluid (CSF). The CSF immune system is more specialized and is quite different from the blood in the composition of cell types, Gate explains. Since Alzheimers is a brain disease, it made sense to look at the brains immune system via the CSF.

For years, researchers had been administering a highly accurate diagnostic test for Alzheimers that measures protein hallmarks of the disease in CSF collected via a spinal tap. In conducting this test, researchers take a sample of CSF and use a centrifuge to separate the liquid from the solids, which contain the cells. The liquid portion is then tested, while the solid portion is generally discarded. Gate realized that he could use that cell portion.

Their early findings were intriguing, and more than that, seemed to be something really novel, says Gate.The results showed elevated levels of a particular type of immune cell called CD8+ T cells in the blood and CSF of Alzheimers patients, as well as in the postmortem brains of people with the disease. Whats more, some of these T cells had rapidly proliferated in a process known as clonal expansion, which happens when they encounter a pathogen, and some of those clonally expanded T cells carried sequences encoding receptors that target a common human herpesvirus, Epstein-Barr virus (EBV).

The pair submitted a paper to Nature. While it was initially rejected, the feedback and requests for more information they got steered them in the right direction, says Gate, and the study was published in the journal in 2020. Meanwhile, Gate, Wyss-Coray, and colleagues filed a patent application based on their methods for measuring T cell markers associated with Alzheimers disease.

Gate and Wyss-Coray cautioned in the paper that there isnt yet enough evidence to draw a causal link between EBV and Alzheimersthat is, it's unclear if EBV could make a person more susceptible to this disease or exacerbate cognitive decline. Indeed, researchers have previously published conflicting evidence of possible connections between the two.

Nevertheless, the realization that the state of the immune cells in the spinal fluid could be linked to Alzheimers was significant, says Wyss-Coray. It led to a really great discovery and, I think, a shift in technology and how people look at the immune system in the brain. Now, all around the world, people are looking at the solid portion of these test samples in a new way, Wyss-Coray adds. Before Davids paper, almost everybody just sort of threw the thing away.

Gate started his own lab at Northwestern University in September of this year and plans to continue studying the intersection between the immune system and neurodegenerative disease.

Were really excited to have him, says Robert Vassar, the scientific director of behavioral neurology at Northwestern, who recruited Gate, adding that many people at Northwestern are interested in collaborating with their new colleague. Hes going to be rising quickly and really making a huge impact, I think, on the field.

Continue reading here:
David Gate Probes Links Between Alzheimers and the Immune System - The Scientist